Zimmer C, Gottschalk J, Goebel S, Cervos-Navarro J
Institute of Neuropathology, Free University of Berlin, Federal Republic of Germany.
Virchows Arch A Pathol Anat Histopathol. 1992;420(2):121-6. doi: 10.1007/BF02358802.
The aim of this study was to determine the specificity and sensitivity of the commercially available, monoclonal anti-melanoma antibody HMB-45 in brain tumours and peripheral nerve sheath tumours. Hence, a series of 155 different non-melanotic tumours of the central and peripheral nervous system were examined immunohistochemically. The brain lesions consisted of primary tumours and metastases from various carcinomas. Twenty melanotic tumours (cerebral metastases of malignant melanomas, meningeal melanomatosis, meningeal melanocytomas) and dermal blue cell naevi served as controls. All melanotic tumours stained positive. Furthermore, a positive immunohistochemical reaction was observed in the following non-melanotic tumours: gliosarcomas, primitive neuroectodermal tumours, ependymoma, malignant schwannomas and different intracranial hamartomas. Two plasmacytomas and 4 metastatic carcinomas also revealed positive staining for HMB-45. Our results confirm the necessity for cautious interpretation of HMB-45 immunoreactivity as a tool in the immunohistochemical characterization of nervous system tumours.
本研究的目的是确定市售的单克隆抗黑色素瘤抗体HMB - 45在脑肿瘤和周围神经鞘瘤中的特异性和敏感性。因此,对一系列155例不同的中枢和周围神经系统非黑色素瘤肿瘤进行了免疫组织化学检查。脑病变包括原发性肿瘤和各种癌的转移瘤。20例黑色素瘤肿瘤(恶性黑色素瘤脑转移、脑膜黑色素沉着症、脑膜黑色素细胞瘤)和皮肤蓝色细胞痣作为对照。所有黑色素瘤肿瘤均染色阳性。此外,在以下非黑色素瘤肿瘤中观察到阳性免疫组织化学反应:胶质肉瘤、原始神经外胚层肿瘤、室管膜瘤、恶性神经鞘瘤和不同的颅内错构瘤。2例浆细胞瘤和4例转移性癌也显示HMB - 45染色阳性。我们的结果证实,在将HMB - 45免疫反应性作为神经系统肿瘤免疫组织化学特征分析工具时,必须谨慎解读。